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Introduction
Spherical crystallization technology which has been 
used to enlarge the size of the particles, has attracted 
the attention of pharmaceutical industry in the last 
decades, where small crystals are often produced by 
crystallization but their handing out is then very 
difficult and costly. The technology has the capability 
to agglomerates the crystals directly inside the reactor 
where the properties of agglomerates can be 
controlled.1-3 However, this method is still not widely 
employed in pharmaceutical industry. This could be 
due to the lack of understanding and governing the 
process parameters that permit the efficient production 
of agglomerates.  
In general, spherical crystallization methods for the 
preparation of agglomerates can be classified into two 
main categories spherical agglomeration and the quasi 
emulsion solvent diffusion (QESD). The spherical 
agglomeration consists of crystallization of fine 
crystals of a drug followed by the aggregation by 
employing water –immiscible solvents (e.g., 
methylene chloride or chloroform, as binder liquid.4,5 
Nonetheless, in case of using these solvents, they can 
increase ecological and human safety worries over 
solvents left in the samples, thus they are not 
suggested for the routine production process. 
Conversely, QESD is built on the miscibility of 
solvents with water. QESD technique consists of the 
emulsification of organic solution of drug which is 
miscible with water and it also contains stabilizers. On 
shifting a temporary O/W emulsion into water, 
droplets solidify promptly as a result of the diffusion 
of the organic solvent out of the droplets to the 
external phase. Indeed, in this method, the 
intermediate step of agglomeration is establishing an 
emulsion, which is turned into agglomerates. The 
process is reliant on sensitive to the selection of 
solvent and the stabilizer. The stabilizer plays the role 
of dispersing emulsion droplets and preventing the 
emulsion droplets from coalescence. This critical 
point distinguishes QESD from simple precipitation 
processes. Unfortunately, the selection is dependent 
on the empirical approaches. At present, the 
manufacture of drug agglomerates via QESD needs a 
number of trial and error experiments since the 
systematic knowledge about the process is absent. 
Despite the industrial significance of the process, the 
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Abstract 
Purpose: The quasi-emulsion solvent diffusion (QESD) has evolved into an effective 
technique to manufacture agglomerates of API crystals. Although, the proposed technique 
showed benefits, such as cost effectiveness, that is considerably sensitive to the choice of a 
stabilizer, which agonizes from a absence of systemic understanding in this field. In the 
present study, the combination of different solvents and stabilizers were compared to 
investigate any connections between the solvents and stabilizers. 
Methods: Agglomerates of celecoxib were prepared by QESD method using four different 
stabilizers (Tween 80, HPMC, PVP and SLS) and three different solvents (methyl acetate, 
ethyl acetate and isopropyl acetate). The solid state of obtained particles was investigated 
by differential scanning calorimetry (DSC) and Fourier transform infrared (FT-IR) 
spectroscopy. The agglomerated were also evaluated in term of production yield, 
distribution of particles and dissolution behavior. 
Results: The results showed that the effectiveness of stabilizer in terms of particle size and 
particle size distribution is specific to each solvent candidate. A stabilizer with a lower HLB 
value is preferred which actually increased its effectiveness with the solvent candidates with 
higher lipophilicity. HPMC appeared to be the most versatile stabilizer because it showed a 
better stabilizing effect compared to other stabilizers in all solvents used. 
Conclusion: This study demonstrated that the efficiency of stabilizers in forming the 
celecoxib agglomerates by QESD was influenced by the HLB of the stabilizer and 
lipophilicity of the solvents. 
 
Research Article 
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selection of a stabilizer in agglomeration techniques 
has not systematically been studied. Furthermore, as 
in previous studies each researcher has used different 
processing and characterization conditions, thus, it is 
extremely difficult to compare the results of previous 
reports. The main aim of the present study is to show 
that performing experiments under similar conditions 
can generate a knowledge which the crystallization 
process in a controlled fashion can be tailored to 
produce agglomerates.  
In the present investigation, the combinations of 2 
commonly used stabilizers (HPMC and PVP), 2 
surfactants (Tween 80 and SLS) and 3 solvents 
(methyl acetate, ethyl acetate and isopropyl acetate) 
were investigated under constant processing and 
characterization conditions. 
 
Materials and Methods 
Materials 
Celecoxib (CLX) was supplied by (Arastoo chemical 
company, Iran), solvents (Merck, Germany), HPMC 
(Colorcon, UK), povidon (PVP K30) (BASF, 
Ludwigshafen, Germany), Tween 80 (Merck 
Schuchardt OHG, Hohenbrunn, Germany), SLS 
(Scharlau Chemie SA, the 
European Union) were used.  
 
Preparation of agglomerates  
Three different organic solvents as good solvent 
including methyl acetate (MA), ethyl acetate (EA), 
and isopropyl acetate (IPA) were employed as a 
dispersed phase for making oil-in-water emulsions 
(O/W). Crystallization was carried out in a 
cylindrical vessel equipped with three baffles. 
Celecoxib (CLX) was dissolved in 15 ml of good 
solvent. The solvent solutions were then poured 
dropwise during 3 min, under stirring (500 rpm), into 
485 ml of water containing 0.1% w/v emulsifier. 
Tween 80, SLS, PVP or HPMC were used as 
emulsifiers. After 15 min agitation by a propeller 
type stirrer, the agglomerates were separated from 
the solution by filtration under vacuum and then 
were placed in a thin layer in an oven at 60°C for 3 
h. The solubility of organic solvents in water was the 
basis of the selection of the solvents in making 
solvent-in-water emulsion.6 
 
Determination of solubility 
The solubility of CLX was investigated, by adding 
the excess drug particles in the solvents and shaking 
the glass vials for specific time until reaching 
equilibrium conditions. A 0.45 µ - membrane filter 
solution was used to filter the solutions. UV-
Spectrophotometer was used to determine the 
absorbance of the filtrate solutions after suitable 
dilution. The experiments were undertaken at 25 ± 0.1°C. 
The mean of three determinations was used to 
calculate the solubility of the drug in the solvents. 
 
The agglomerates characterization 
Particle size:An optical microscope (Nikon Labophot, 
Tokyo, Japan) was used to determine the size of 
agglomerates and their primary crystals. To measure the 
initial size of crystals of the agglomerates, the 
agglomerates were fragmented in distilled water 
containing polysorbate 80 (Tween 80; 0.05%) using 
ultrasonicator (VC 130, Sonics and Materials Inc., 
USA) at 100W before determining the size of particles. 
Mineral oil was used to suspend a small amount of 
powder and the suspension was spread onto a 
microscope slide to measure the size of the particles by 
optical microscope via a miniature video camera. The 
largest diameter of at least 100 particles under the 
microscope was measured by the scion image analysis 
software. We confirmed that the dissolution of the drug 
in the dispersing medium was negligible for the 
measurement of particle size due to its extremely low 
solubility.  
To measure the agglomerates size, light microscopy 
pictures of the particles were captured. The mean 
particle size of a single particle was denoted as the 
mean length of the distance determined at 2° intervals 
connecting two outline points passing through the 
center of gravity of the particle. Each determination 
was carried out on a minimum of 100 particles. 
 
Sieving: It has been shown that the size of particles 
could affect the mechanical and dissolution 
performance of particles.7 In order to minimize the 
effects of CLX particle size on friability and dissolution 
rate of obtained samples, the same sieved fraction of 
250 - 500 µm was used to characterize all CLX 
samples. CLX crystallized samples were poured 
separately onto the top of 500 µm sieve which was 
placed above a 250 µm sieve. The vibratory mechanical 
shaker was then tightened closely and operated for 10 
min, after which the particles retained on the 250µm 
sieve were collected.  
 
Determination of agglomeration yield: In order to 
determine the percentage yield, the obtained 
agglomerates were dried at 60 °C for 3 h and the final 
weight was recorded after drying. Then the following 
equation was used to calculate the percentage yield (Eq. 
1). The procedure was repeated for three batches of the 
samples.                     ሺ ሻ                ሺ            ሻ                ሺ    ሻ      Eq. 1 
Dissolution studies 
The agglomerates with diameters between 250 and 500 
µm was selected for dissolution studies. The dissolution 
was performed by the paddle method and the 
dissolution medium was distilled water. The paddle 
speed was set at 50 rpm and the bath temperature was 
kept at 37 °C. The sink conditions was maintained by 
adding 0.25% (w/v) SDS in 1000 ml distilled water.8,9 
Each vessel was introduced the amount of sample 
equivalent to 40 mg celecoxib. At pre-determined time 
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intervals, samples were withdrawn from the vessels 
through a 5 µm membrane filter (Millipore) followed 
by their spectrophotometric analysis employing a UV 
detector (UV-160A, Shimadzu, Japan) at 253 nm. The 
number of dissolution run was three. The initial results 
showed that SDS did not have any interference with 
celecoxib at 253 nm. 
 
FT-IR spectroscopy 
Infrared spectra were recorded using an FT-IR 
spectrophotometer (M-B-100, Bomem, Canada) 
utilizing potassium bromide discs. These KBr discs 
containing 2-3 mg drug were made by grinding 2-3 mg 
of sample with 25-50 mg of potassium bromide and 
compressed by a hydraulic press (Riken Seiki, Japan) at 
10 MPa for 2 min. The data region was 4000–500 cm−1. 
  
Differential scanning calorimetery (DSC)  
Different polymorphic composition of pharmaceutical 
powders with different melting points can be studied by 
DSC. The DSC was calibrated using indium and lead 
standards. Samples of the crystals (3–5 mg) were 
heated (range 25-250°C) at 10 °C/min in crimped 
aluminum pans under a nitrogen atmosphere. The en-
thalpy of fusion and melting point were automatically 
calculated using the software provided by Shimadzu 
(Japan). 
 
Statistical evaluation of data 
All data reported in the present study were the mean ± 
standard deviation (SD). ANOVA was used to compare 
the mean values (more than two groups) of the data 
obtained and comparison between the two means was 
determined using the Tukey’s test with statistical 
significance evaluated at P < 0.05. 
 
Results and Discussion 
Mechanism of agglomeration of crystals 
The production of agglomerates by QESD technique 
starts with the preparation of O/W emulsion (in this 
case, oil is an organic solvent which is also partially 
miscible with water and it contains the drug). The oil 
phase acts as an internal phase. MA, EA and IPA 
solvents with different water miscibility (4.3-25% v/v) 
and having low toxicity were employed to manufacture 
the primary emulsion.6 Preliminary results showed that, 
there are a number of variables can have an impact on 
the globule size of the emulsions (internal phase) and 
possibly the behavior of the resulting solid particles. 
The parameters affecting the droplet size and properties 
of the particles could be phase ratio, the stabilizer type 
and its concentration, mixing technique, processing 
temperature, and technological conditions of 
manufacturing. In order to cut down the number of 
experiments, the emulsions were manufactured at a 
constant phase ratio using pure water as continuous 
phase and 0.1 % stabilizer in identical condition, while 
the influence of different stabilizers was investigated. 
Safe and efficient stabilizers (Tween 80, HPMC, PVP 
and SLS) were selected in the preparation of 
agglomerates. It should be mentioned that even when 
pure water was used as antisolvent, the size of 
agglomerates was larger compared to the starting 
material. This can be explained in terms of the phase 
separation created upon mixing of partially water 
miscible solvents and water. To explain the formation 
of the agglomerates, 3 steps must be taken into account 
to: formation of emulsion droplets, creation of 
supersaturation by mass transfer and crystallization of 
drug into droplets. It has been recognized that the size 
of the obtained particles is reliant on the size of droplets 
throughout the emulsification step.10 It can be 
concluded that as the size of droplets controls the size 
of the final particles, therefore, smaller droplets can 
produce smaller particles.  
During the emulsification of organic solution in the 
aqueous phase, a hydrophobic surface is formed and the 
energy of the system increases. In order for the system 
to have low surface free energy the droplets normally 
aggregate and consequently coarse particles with wide 
particle size distribution (PSD) are formed. If the added 
stabilizing agent has any affinity to the surface of the 
droplets, then, it can cover the newly formed surface 
spontaneously. Therefore, the surface energy and hence 
the enthalpy of the system are reduced.11  
In fact, the adsorption of stabilizer to the surface of the 
formed droplets, once the optimum packing of the 
stabilizer has been reached, can hinder coalescence of 
droplets through steric or electrostatic stabilization and 
thus droplets with smaller size and tight distribution are 
produced.12-15 As mentioned above, the formation of 
finer and more homogeneous droplets, in turn, allows 
the formation of smaller particles with narrower PSD.  
It can be predicted that the nature of the stabilizer could 
be the main reason for the efficient formation of 
droplets and stabilization of the agglomerates. The 
stabilizer should show sufficient tendency to the droplet 
surface as well as they should form a s mechanical and 
thermodynamic barrier at the interface that retards the 
approach and coalescence of individual emulsion 
droplets.16 If the stabilizer has a hydrophobic region, it 
will have a greater affinity to organic solution droplets 
(hydrophobic droplets), thus, more surface coverage 
will be achieved. On the other hand, in order to avoid 
the aggregation of particles and encourage segregation, 
it is necessary that a stabilizer should posses a 
hydrophilic moiety with sufficient kinetic energy.17 
 
Particle size  
Table 1 summarizes particle size results for 
agglomerates obtained in the presence of different 
stabilizers prepared with MA, EA and IPA. The 
presence of stabilizers in the antisolvent was able to 
considerably decrease the particle size of the made 
agglomerates due to inhibition of coalescence. The 
most successful decrease in particle size was observed 
for the sample obtained in the presence of HPMC. The 
smallest particles with a median diameter of 100 µm 
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were formed in the case of IPA solvent when HPMC 
was present in antisolvent. HPMC not only decreased the 
median particle size but also capable of formation the 
agglomerates with narrower PSD (smaller ϭ) compared 
to control sample. This is a general consideration for the 
entire agglomerates obtained with HPMC. 
 
Table 1. Production yield and size of agglomerates 
samples Yield (%) Median (µm) ϭ ;µmͿ 
MA(SLS) 88±5 215 340 
MA(TW80) 62±4 420 365 
MA(PVP) 77±3 260 360 
MA(HPMC) 84±3 180 300 
MA 92±3 830 380 
EA(SLS) 86±4 270 280 
EA(TW80) 77±5 570 350 
EA(PVP) 83±3 525 280 
EA(HPMC) 84±3 135 130 
EA 91±4 610 325 
IPA(SLS) 81±4 815 180 
IPA (TW80) 76±4 875 195 
IPA(PVP) 88±5 810 330 
IPA (HPMC) 75±3 100 85 
IPA 89±3 840 265 
 
Since the polymer solutions had a very low 
concentration (0.1%w/v), factors such as viscosity was 
unlikely to play an important role in the prepation of 
agglomerates. Therefore, the differences may be mainly 
related to the affinity of the stabilizers to the droplets 
surfaces. These data showed that HPMC chains are 
firmly stick to the droplets surface and form a stable 
and rigid layer which can have a strong protective 
effect. In contrast, PVP did not reserve the physical 
properties of the dispersion as effectively as HPMC. 
PVP reduced the median particle size, however, 
coalescence and aggregation of particles were always 
observed in these batches (Figure 1). Upon emulsion 
formation, the stabilizer can make it stable, probably by 
remaining at the liquid–liquid interface and making the 
emulsion droplets more rigid then to prevent 
coalescence of the droplets. This deliberation could be 
stretched to explain the changes between the polymers 
used as stabilizer (HPMC and PVP). PVP which has a 
higher solubility parameter and thus lower 
hydrophobicity than HPMC can provide weaker 
protection for the droplets, because it is more likely to 
be present in the aqueous phase rather than being 
absorbed on the particle surface. In contrast, HPMC can 
be adsorbed onto the surface of the droplets in order to 
lower the interfacial tension due to its surface activity.18 
As HPMC contains hydrophobic substituents (methoxyl 
group) and PVP is more hydrophilic, therefore, it is 
expected that HPMC particles should have higher 
affinity for hydrophobic droplets compared to PVP. 
These findings are in agreement with the results 
reported in other works associated with stabilization of 
drug crystals. Rasenack et al. showed that HPMC, 
methylhydroxyethyl cellulose (MHEC) and polyvinyl 
alcohol (PVA) most effectively inhibited crystal growth 
of ibuprofen.19 They found out that the particle size of 
ibuprofen decreased as the hydrophobicity of excipient 
increased. It has also been reported that the adsorption 
of polymers on hydrophobic silicon dioxide increased 
with increasing hydrophobicity of the polymers.20 In 
another work, it has been reported that cellulose ethers 
containing hydrophobic groups (as HPMC) adsorbed 
onto hydrophobic siramesine surfaces while more 
hydrophilic derivates (as HEC) show a lower tendency 
for adsorbing onto the solid–liquid interface.21 
Moreover, the stability of the polymeric nanoparticles 
was also correlated to the affinity of the stabilizers for 
the droplets surface.22,23 In a few studies which PVP 
was used as a stabilizer, low efficiency of PVP was 
referred to no distinct hydrophobic units driving the 
adsorption of polymer chains.24-26 This interpretation 
was also verified by other hydrophilic additives. For 
example, Eerdenb rugh et al. showed that PEG with a 
mainly hydrophilic molecule structure did not stabilize 
the formed crystals effectively for a range of drugs 
studied due to its high hydrophilicity.27  
 
 
Figure 1. Optical microscopic image of agglomerates made of 
IPA, a: SLS, b: tween, c: PVP, d: HPMC.   
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Comparing the results of surfactants, SLS and tween 
80, showed that when tween (non-ionic surfactant) was 
used as a stabilizer, larger agglomerates were formed 
regardless of solvent type compared to SLS (anionic 
surfactant). Surfactants have a hydrophobic and 
hydrophilic part of the molecule which are shown in 
Figure 2. This Figure shows the presence of 
polyethylene glycol tail (PEG) as hydrophilic domains 
and hydrocarbon chain (R groups) as hydrophobic 
region for tween 80 molecule. In case of SLS, the 
hydrophilic part of this anionic surfactant (sulphate 
group) has high hydrophilicity positioned in a small 
area. In contrast to SLS structure, polysorbate 80 with a 
PEG chain have a long hydrophilic chain where the 
hydrophilicity is not positioned in small area. It has 
been demonstrated that aggregation of surfactants and 
consequently their efficiency as stabilizer is controlled 
by a balanced molecular geometry.28 A critical packing 
parameter, Pc as the ratio of volume to surface area is 
defined (equation (2))      ሺ      ሻ  Eq. 2 
Where ao is the minimum interfacial area occupied by 
the hydrophilic group, v is the volume of the 
hydrophobic tail and lc is the maximum extended chain 
length of the tail in the micelle core.  
In the case of tween, large interfacial area (ao) due to 
large head group ethylene oxide chain leads to low the 
value of the packing parameter (Pc) which may 
contribute to low efficiency of this surfactant. 
Furthermore, higher efficiency of SLS may also be 
attributed to its smaller molecule (MW: 288) than 
tween 80 (MW: 1310). The small size of SLS may be 
expected to result in faster diffusion to the droplet 
surface and more rapid adsorption kinetics at the 
surface, to inhibit the otherwise coalescence of 
droplets.29 However, since tween has higher molecular 
weight, it will take longer to diffuse and adsorb onto the 
droplets surfaces. Similar results have been reported by 
others where different stabilizers have been used to 
stabilize drug crystals and prevent their crystal growth. 
In these studies, it has been demonstrated that the small 
size of stabilizer allows it to diffuse more quickly to the 
surface of drug crystal and, therefore, may help 
stabilize it before crystallization sets in.30,31 
 
Figure 2. Structure of SLS and tween 80. 
 
For all solvents, it was obvious that the effect of the 
stabilizer on the size of the agglomerates was 
dependent on the type of solvent. The differences 
between solvents could be attributed to their 
hydrophobicity: IPA has longest hydrocarbon chain 
and thus highest hydrophobicity; whereas MA with 
shortest hydrocarbon chain is least hydrophobic. EA 
takes an intermediate position in terms of 
hydrophobicity. On the other hand, HLB value of the 
stabilizers can be ranked as 
SLS>PVP>tween>HPMC.31,32 
The use of SLS, PVP and tween produced moderate 
effects on the particle size of the agglomerates when 
MA and EA were employed, but in case of IPA poor 
effects was observed. In fact, in the case of IPA, very 
similar particle sizes were observed in relation to pure 
water if SLS, PVP and tween (Figure 1) were applied. 
For all solvents examined, the use of HPMC produced 
finer particles than those obtained using other 
stabilizers. However, the agglomerates made in the 
presence of this stabilizer became smaller and 
relatively more homogenous in size by increasing the 
hydrophobicity of the solvent and consequently, the 
highest efficiency of HPMC was found in the IPA 
solvent (Figure 3). Therefore, the efficiency of 
stabilizer was assumed to be influenced by the degree 
of hydrophoicity of the solvent. 
 
Yield  
Drug crystallized in the absence of stabilizer formed 
the agglomerates with a percentage yield of 89-92% 
(w/w), whereas all other crystallized drug – stabilizer 
products generated a lower yield ranging between 62 
and 88 % (w/w) (Table.1). The observed changes in 
the shape of the agglomerates (Figure 1), and 
reduction in the yield are indicative that stabilizers 
had a marked effect on the crystallization of CLX. The 
effects of additives on the shape and yield of crystals 
have been demonstrated in many other studies. For 
example, in the crystallization of phenytoin in the 
presence of three different ester homologues of 
diphenylhydantoin, it has been shown that changes in 
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crystal habit and remarkable fall in crystal yield was 
due to the adsorption of additive onto the crystal faces 
of phenytoin.33-35 In another study, it has been shown 
that the crystallization of paracetamol from water in 
the presence of gelatin or PVP, changed the crystal 
habit of paracetamol and caused a decrease in crystal 
yield.36,37 The reduction in the yield of the 
agglomerates made in the presence of stabilizer could 
be due to the influence of stabilizer on drug solubility. 
Greater drug solubility in the presence of stabilizer 
(Table 2), may result in incomplete solvate of the 
initial crystals, leading to a reduction in the yield for 
agglomerates. As expected, the lowest yield of the 
agglomerates was found in the presence of tween, 
stabilizer with highest improving effect on the 
solubility of the drug. In the case of polymers, PVP 
and HPMC, the formation of viscose gel around 
particles by polymers and consequently generation of 
sticky agglomerates may also contribute to lower 
yield. During the process, the sticky particles adhered 
to the impeller and also to the crystallizer wall which 
these led to a reduction in the production yield.38 
 
 
Figure 3. Particle size distribution of the agglomerates 
prepared in presence of HPMC.  
 
Table 2. Solubility of drug in water containing stablizer  
Stabilizers 
Solubility of drug in  
Water containing 0.1% 
stablizer (µg/ml) 
PVP 14.5±1.2 
HPMC 15.9±2.0 
SLS 18.1±2.0 
Tween 80 23.5±2.2 
Without 
stablizer 
5.6±3.0 
 
Dissolution  
The dissolution behavior of the agglomerates performed 
in the dissolution medium containing 0.25% (w/v) SLS 
were shown in Figure 4. To assess the influence of 
stabilizers on the dissolution of the drug, the amount of 
drug dissolved within 90 minutes was analyzed 
statistically. Dissolution results indicated that 
stabilizers had no strong effect on the dissolution rate of 
CLX from the agglomerates which could be explained 
as follows. The most important effect of stabilizers 
influencing the dissolution profile of crystals is 
distribution behavior. Better wettability of crystals and 
consequently their easy dispersion in dissolution 
medium is the main cause of increasing dissolution rate 
of the drug in presence of stabilizers.39 However, taking 
into account this fact that during dissolution tests the 
agglomerates did not break due to lack of disintegrant, 
the role of stabilizer in the distribution of crystals could 
be ruled out. Moreover, the dissolution happens from 
the agglomerated particle surfaces in direct contact with 
the dissolution medium as well as from diffusion 
through the water-filled pores of the agglomerates.40 
Consequently, it is supposable that different dissolution 
rate of drug from the agglomerates would be mainly 
attributed to the different porosity of the agglomerates. 
For example, in the case of EA, the agglomerates made 
in the presence of SLS dissolved a little faster than the 
control agglomerates which could be attributed to the 
moveable structure of the agglomerates (Figure 1). It is 
obvious that agglomerates with more pores allow faster 
penetration of water leading to quicker dissolution of 
drug from the agglomerates, as discussed above.  
 
FT-IR 
The molecular states of CLX are studied by means of 
FT-IR spectroscopy, according to the information on 
vibration in the powder composition. The FT-IR of the 
untreated drug was shown in Figure 5. For comparison, 
the FT-IR spectra of prepared agglomerates made of 
IPA was also shown in this Figure. In the spectrum of 
the CLX agglomerates made in the presence of tween, 
SLS and PVP, peaks relative to CLX were present 
without any change (data not shown), however, the shift 
of band of CLX at 1150 cm-1 to 1132 cm-1 was detected 
in the FT-IR spectrum of the agglomerates prepared in 
the present of HPMC. The FT-IR spectrum of celecoxib 
showed diagnostic bands at 1345 and 1150 cm-1 (S=O 
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asymmetric and symmetric stretching) and at 1227 cm-1 
(C-F stretching). Furthermore, medium intensity bands 
at 3334 and 3227 cm-1 (N-H stretching vibration of 
SO2NH2 group) were seen as a doublet.41,42 Good match 
between the spectrum of the agglomerates prepared in 
absence of stabilizer and untreated drug revealed that 
the crystallization process does not affect the chemistry 
composition of the drug. In the spectrum of the CLX 
agglomerates made in presence of tween, SLS and PVP, 
peaks relative to CLX were present demonstrating no 
interactions between the drug and the stabilizers (data 
not shown). However, the negative shift of symmetric 
S=O group of CLX from 1150 cm-1 to 1132 cm-1 was 
observed in the FT-IR spectrum of the agglomerates 
prepared in the present of HPMC. Concerning the 
molecular structure of the celocoxib and HPMC the 
formation of hydrogen bonding is possible. The 
hydrogen bonding could be formed between the S=O 
(proton acceptor) of CLX and OH (proton donor) group 
of HPMC. FT-IR spectrum of these agglomerates 
supports our assumption that HPMC to be the most 
efficient stabilizer. 
 
Differential scanning calorimeter (DSC) 
DSC analyses were performed to differentiate any 
changes in solid state of CLX in various formulations. 
Figure 6 shows the DSC thermograms of original 
celecoxib and different samples obtained by IPA in 
presence of different stabilizers. This Figure 
demonstrated the uniformity of crystalline structure in 
all samples. The results ruled out any significant 
difference between melting points of original CLX 
(160 °C) and the treated samples. All samples, 
irrespective of used stabilizer exhibited a distinctive 
sharp peak (melting point), which indicated that the 
CLX was unaffected by hydration or solvation during 
crystallization with different stabilizers. 
 
Figure 4. Dissolution profile of the agglomerates 
prepared with (from top) MA, EA and IPA; □: SLS, ◊: 
tween, ∆: PVP, ×: HPMC, ○: without stabilizer.  
 
 
Figure 5. FT-IR spectrum of the samples from top; untreated CLX, agglomerates prepared with IPA without stabilizer and agglomerates 
prepared with IPA in presence of HPMC. 
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Figure 6. DSC scans of the agglomerates prepared with IPA in presence of; 1: SLS, 2: tween, 3: PVP, 4: HPMC and untreated celecoxib. 
 
Conclusion 
It can be concluded that, the type of stabilizer is pivotal 
to obtain CLX agglomerates via emulsification-
diffusion method. In this study, the effect of various 
stabilizers in relation to different solvents on the 
stability of produced agglomerates of CLX was tested, 
as different stabilizers has different capacity to prevent 
coalescence of droplets and consequently the formation 
of smaller agglomerates with tight particle size 
distribution. The particle size of agglomerates prepared 
in presence of HPMC was significantly smaller than 
that stabilized with PVP, SLS or Tween, in all solvents. 
Moreover, a dispersion prepared with HPMC showed a 
tight particle size distribution. It should be mentioned 
that HPMC effectiveness increased with the solvent 
candidates with higher lipophilicity. It was shown that 
the useful stabilizers for hydrophobic organic solution 
in aqueous phase are those ones with a hydrophobic 
substituent and hydratable functional groups. The 
quasi-emulsion solvent diffusion method using 
judiciously selected type of stabilizer and solvent can 
be a potential approach for preparing agglomerates of 
drugs with promising pharmaceutical properties. 
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